Paid Clinical Trials Madison
Discover 308 paid clinical trials in Madison, Wisconsin. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
CFT1946A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 As Monotherapy and Combination Therapy in Subjects with BRAF V600 Mutant Solid Tumors
Sponsor:
C4 Therapeutics, Inc.
Location:
Code:
NCT05668585
Conditions
Solid Tumors
Melanoma
NSCLC
CRC
ATC
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
CFT1946
Trametinib
Cetuximab
Casdozokitug & Toripalimab, BevacizumabA Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Sponsor:
Coherus Biosciences, Inc.
Location:
Code:
NCT06679985
Conditions
Hepatocellular Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Casdozokitug
Toripalimab
Bevacizumab
Cabozantinib & NivolumabStudy of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
Sponsor:
Rana McKay, MD
Location:
Code:
NCT05502315
Conditions
Castration-resistant Prostate Cancer
Metastatic Cancer
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Cabozantinib
Nivolumab
VITRAKVIStudy to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
Sponsor:
Bayer
Location:
Code:
NCT04142437
Conditions
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
larotrectinib(Vitrakvi, BAY2757556)
Direct-acting AntiviralsProphylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients
Sponsor:
Johns Hopkins University
Location:
Code:
NCT05653232
Conditions
HCV
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Prophylaxis (P2W)
Transmit and Treat (T&T)
Rilvegostomig & Fluoropyrimidine & Trastuzumab DeruxtecanA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Sponsor:
AstraZeneca
Location:
Code:
NCT06764875
Conditions
HER2-positive Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Rilvegostomig
Trastuzumab deruxtecan
Trastuzumab
Pembrolizumab
5-fluorouracil
Durvalumab & Ablative RadiationDurvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
Sponsor:
University of Chicago
Location:
Code:
NCT05068232
Conditions
Small-cell Lung Cancer
Extensive-stage Small-cell Lung Cancer
Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Ablative Radiation
Durvalumab
Etoposide
Carboplatin
LY3962673MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT06586515
Conditions
Pancreatic Ductal Adenocarcinoma
Non-small Cell Lung Cancer
Colorectal Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
LY3962673
Cetuximab
Gemcitabine
nab-paclitaxel
Oxaliplatin
Dipraglurant with LevodopaDipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
Sponsor:
Addex Pharma S.A.
Location:
Code:
NCT04857359
Conditions
Parkinson Disease
Dyskinesia, Drug-Induced
Dyskinesias
Eligibility Criteria
Sex: All
Age: 30 - 70+
Healthy Volunteers: Not accepted
Interventions
Dipraglurant
Placebo